The ARFGEF family, short for ADP-ribosylation factor guanine nucleotide exchange factors, encompasses a group of proteins that are key regulators of vesicle trafficking within cells. These proteins function primarily as guanine nucleotide exchange factors (GEFs) for ADP-ribosylation factors (ARFs), which are small GTP-binding proteins involved in vesicle formation and transport. ARFGEFs catalyze the exchange of GDP for GTP on ARFs, activating them to initiate the budding of transport vesicles from various membranes, including the Golgi apparatus and the endoplasmic reticulum. Members of the ARFGEF family, such as BIG1, BIG2 and BIG3, are particularly important in the regulation of vesicle trafficking in the secretory pathway, which is crucial for the transport of proteins and lipids throughout the cell. Dysregulation of ARFGEF function has been implicated in several diseases, including neurological disorders and cancer, due to their role in intracellular transport and signaling.
Targeting ARFGEFs (ADP-ribosylation factor guanine nucleotide exchange factors) with small molecules allows for a direct investigation into the molecular mechanisms of vesicle trafficking and membrane dynamics in cells. By inhibiting or disrupting ARFGEF activity, these small molecules can help delineate the specific roles of ARFGEFs in processes like protein and lipid transport, Golgi apparatus function, and cell signaling. This approach not only aids in understanding the fundamental aspects of cell biology but also provides insights into targeting of ARFGEFs in diseases where their dysregulation is a contributing factor, such as in certain cancers and neurological disorders.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Known to inhibit the function of ARFGEFs including BIG1 and BIG2 by stabilizing their interaction with ARFs in their GDP-bound state, disrupting Golgi structure and function. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Specifically inhibits ARFGEF1 (BIG1) and ARFGEF2 (BIG2), affecting ARF-mediated Golgi to ER retrograde transport. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
While its primary target is cytohesins (another subgroup of ARFGEFs), it may also affect BIG family ARFGEFs due to the similarity in mechanism. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $89.00 $288.00 | 1 | |
Though targeting the Exocyst complex, it indirectly affects processes regulated by ARFGEFs, including vesicle trafficking. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Known for its actin-disrupting properties, it indirectly impacts vesicle trafficking, potentially affecting ARFGEF-regulated processes. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A Cdc42 inhibitor, which indirectly affects pathways involving ARFGEFs. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Mainly inhibits clathrin-mediated endocytosis but could indirectly affect ARFGEF functions. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
A p97/VCP inhibitor that can indirectly affect the function of ARFGEFs, particularly in the context of ER-associated degradation. | ||||||